Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

Abstract Background Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM), leading to unprecedented responses in this patient population. Idecabtagene vicleucel (ide-cel) has been recently approved for treatment of tr...

Full description

Bibliographic Details
Main Authors: Dilara Akhoundova Sanoyan, Katja Seipel, Ulrike Bacher, Marie-Noelle Kronig, Naomi Porret, Gertrud Wiedemann, Michael Daskalakis, Thomas Pabst
Format: Article
Language:English
Published: BMC 2023-04-01
Series:BMC Cancer
Subjects:
Myeloma
CAR-T
Relapsed
Outcome
Ide-cel
Online Access:https://doi.org/10.1186/s12885-023-10824-3

Internet

https://doi.org/10.1186/s12885-023-10824-3

Similar Items